6:01 PM
 | 
Sep 17, 2013
 |  BC Extra  |  Top Story

EC OKs Lemtrada, NICE wants Aubagio data

The European Commission approved Lemtrada alemtuzumab from the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) to treat relapsing remitting multiple sclerosis (RRMS) in patients with active disease defined by clinical or imaging features. The company plans to launch Lemtrada "soon." Last year, Genzyme withdrew MabCampath/ Campath alemtuzumab from the European and U.S. markets to treat B cell chronic lymphocytic leukemia (CLL)...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >